Mycophenolate mofetil is a new immunosupressive drug, exhibiting its effect through inhibition of proliferation of T- and B-lymphocytes. Superior efficacy of mycophenolate mofetil compared to azathioprine, in combination with cyclosporine and prednisone, in the prevention of acute rejection in organ transplantation has made mycophenolate mofetil one of the standard immunosupressive drugs after transplantation. Mycophenolate mofetil also is an interesting candidate drug for many other, mainly auto-immune mediated diseases. The use of mycophenolate mofetil in several of these diseases is discussed. The definitive place of mycophenolate mofetil will depend on the results of randomised trials currently under way. (C) 2000 Elsevier Science B.V.

, ,
doi.org/10.1016/S0300-2977(00)00069-3, hdl.handle.net/1765/62915
The Netherlands Journal of Medicine
Department of Internal Medicine

Smak Gregoor, P.J.H, van Gelder, T, & Weimar, W. (2000). Mycophenolate mofetil, Cellcept®, a new immunosuppressive drug with great potential in internal medicine. The Netherlands Journal of Medicine (Vol. 57, pp. 233–246). doi:10.1016/S0300-2977(00)00069-3